Trial Profile

Open-label Evaluation of Adrabetadex in Patients With Neurologic Manifestations of Niemann-Pick Type C Disease (NPC)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 21 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adrabetadex (Primary)
Indications Niemann-Pick disease type C
Focus Registrational; Therapeutic Use
Sponsors Mandos

Most Recent Events

22 Dec 2023 Status changed from completed to discontinued. The clinical development program of adrabetadex was discontinued because the sponsor determined that its benefit-risk profile was not favorable.
14 Apr 2022 Status changed from active, no longer recruiting to completed.
02 Mar 2021 Planned End Date changed from 31 Jul 2021 to 1 Nov 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com